Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...
The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...
The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...
The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...
Today, a brief rundown of news from Novo Nordisk and Merck & Co., as well as updates from Pfizer, Camp4 Therapeutics and Chai Discovery that you may have missed. AbbVie reached legal settlements ...
The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...
The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback